Back to today’s briefing

Story perspectives

FDA Approves EMBLAVEO: New Hope Against Resistant Infections

2/11/2025

38 4

Summary

Story summary

The FDA has given the green light to AbbVie’s EMBLAVEO, a groundbreaking antibiotic designed to tackle complicated intra-abdominal infections in patients with few treatment options. This innovative drug, developed alongside Pfizer, effectively targets resistant Gram-negative bacteria, offering hope in the fight against antimicrobial resistance. EMBLAVEO is set to hit U.S. markets in Q3 2025.

1 of 1

Story summary

The FDA has given the green light to AbbVie’s EMBLAVEO, a groundbreaking antibiotic designed to tackle complicated intra-abdominal infections in patients with few treatment options. This innovative drug, developed alongside Pfizer, effectively targets resistant Gram-negative bacteria, offering hope in the fight against antimicrobial resistance. EMBLAVEO is set to hit U.S. markets in Q3 2025.